Showing 6761-6770 of 8469 results for "".
- NEMLUVIO Demonstrates Durable Efficacy and Safety in Atopic Dermatitishttps://practicaldermatology.com/news/nemluvio-demonstrates-durable-efficacy-and-safety-in-atopic-dermatitis/2475110/New two-year interim data from the ARCADIA long-term extension study of NEMLUVIO (nemolizumab) showed sustained improvements in skin and itch outcomes. The therapy was approved by the FDA in December 2024 for the treatment of
- Study: Belly Fat More Predictive of Psoriasis Than Overall Body Fathttps://practicaldermatology.com/news/study-belly-fat-more-predictive-of-psoriasis-than-overall-body-fat/2475108/Central adiposity—particularly abdominal fat—is more strongly linked to psoriasis risk than overall body fat, according to a new analysis published in the Journal of Investigative Dermatology.
- INTEGUMENT-INFANT to Test Roflumilast Cream in Children Under Twohttps://practicaldermatology.com/news/integument-infant-to-test-roflumilast-cream-in-children-under-two/2475087/Arcutis Biotherapeutics has announced the enrollment of the first participants in its new phase 2 INTEGUMENT-INFANT study focusing on the safety and tolerability of ZORYVE (roflumilast) cream 0.05% in infants with atopic dermatitis (AD).
- Researcher Elaborates on Vitamin D Pretreatment to Enhance PDT for AKhttps://practicaldermatology.com/news/Researcher-Elaborates-Vitamin-D-Pretreatment-Enhance-PDT-AK/2475053/Vitamin D pretreatment can enhance photodynamic therapy (PDT) treatment of actinic keratoses (AK), and vitamin D receptor alleles correlate with serum vitamin D levels and squamous neoplasia, dermatology resident Taylor Bullock, MD, showed in a presentation at the Noah Worcester Dermatological So
- Probiotic for Oily and Acne-Prone Skin Gets US Patenthttps://practicaldermatology.com/news/Probiotic-Oily-Acne-Prone-Skin-Gets-US-Patent/2474976/A probiotic for managing oily, acne-prone skin was awarded US Patent No. 12,194,068, Codex Labs announced. In an independent clinical trial at Integrative Skin Solutions Research involving 18 male and female subjects with mild to moderate acne, the measured improvement after 8 weeks of Cod
- ZORYVE Foam Cleared by FDA for Full-Body Psoriasishttps://practicaldermatology.com/news/zoryve-foam-cleared-by-fda-for-full-body-psoriasis/2474798/The US Food and Drug Administration (FDA) has approved Arcutis Biotherapeutics’ ZORYVE® (roflumilast) topical foam 0.3% for the treatment of plaque psoriasis in patients aged 12 and older, according to a press release from the manufacturer.
- Analysis Forecasts 140% Rise in Basal Cell Carcinoma by 2050https://practicaldermatology.com/news/analysis-forecasts-140-rise-in-basal-cell-carcinoma-by-2050/2474797/The global burden of skin cancer among adults aged 65 and older has increased steadily over the past three decades and is expected to continue rising through 2050, according to a new analysis of Global Burden of Disease (GBD) Study data.
- Arcutis Announces Expert Statements on Genital Psoriasishttps://practicaldermatology.com/news/arcutis-announces-expert-statements-on-genital-psoriasis/2474665/Arcutis Biotherapeutics, Inc. has announced new consensus statements aimed at improving the diagnosis and management of genital psoriasis, according to a company press release. The 14 statements, developed by a multidisciplinary group of dermatology and immunology experts with the Genital
- Dermeleve to Modify Program for Sampleshttps://practicaldermatology.com/news/Dermeleve-Modify-Program-Samples/2474651/Dermeleve will transition away from its auto-ship model and self-serve request program for samples, but will still offer samples directly to patients and to clinicians who choose to hole wholesale inventory, the company said in an email to partners. “To ensure your patients can still ‘try
- Study: Ultralow-Dose Rituximab Effective in Pemphigushttps://practicaldermatology.com/news/study-ultralow-dose-rituximab-effective-in-pemphigus/2474602/A new 52-week clinical trial found that ultralow-dose rituximab (ULRTX) achieved comparable efficacy, safety, and B-cell depletion to standard and low-dose regimens in patients with moderate-to-severe pemphigus vulgaris (PV) and pemphigus foliaceus (PF).